AbbVie Class Action Lawsuit ABBV | Deadline June 6, 2022

AbbVie is facing a class action lawsuit (AbbVie Class Action Lawsuit) alleging that the Company made materially false and/or misleading statements and/or failed to disclose that:

(1) safety concerns about Pfizer Inc.’s drug Xeljanz extended to Abbvie’s drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.

If you incurred a loss on ABBV stocks purchased between April 30, 2021 and August 31, 2021, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Northern District of Illinois, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until June 6, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.